# OnCo record aeneas (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/aeneas/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "aeneas", "NCT03849768" ;
  schema:name "AENEAS"@en ;
  schema:description "The trial that showed Hansoh's aumolertinib roughly doubles progression-free survival compared with gefitinib in EGFR-mutant lung cancer."@en ;
  schema:url <https://onco.cc/trials/aeneas/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03849768>, <https://doi.org/10.1200/JCO.21.02641> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "3" ;
  schema:startDate "2019-02-01" ;
  onco:related <https://onco.cc/trials/furlong/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/aumolertinib/>, <https://onco.cc/drugs/gefitinib/> ;
  onco:companies <https://onco.cc/companies/hansoh-pharma/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aeneas-j-clin-oncol-2022/> .